F. Schramel

Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

Otto S Hoekstra, Adriaan A Lammertsma, Johan Vansteenkiste, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study

O. Hoekstra, E. Smit, J. Aerts, 2019, British journal of cancer.

The Association Between Gut Microbiome Affecting Concomitant Medication and The Related Effectiveness of Immunotherapy in Patients With Stage IV NSCLC

M. Tonn, B. Peters, E. M. van de Garde, 2021 .

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.

H. Groen, E. Smit, F. Schramel, 2019, Lung cancer.

Effects of structured involvement of the primary care team versus standard care after a cancer diagnosis on patient satisfaction and healthcare use: the GRIP randomised controlled trial

N. D. de Wit, A. May, M. Ernst, 2022, BMC Primary Care.

The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.

F. Schramel, M. Wouters, A. de Boer, 2020, Lung cancer.

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC

F. Schramel, M. van Dartel, A. Pasmooij, 2023, BMC Medical Research Methodology.

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

F. Schramel, M. van Dartel, A. Pasmooij, 2023, BMC Medical Research Methodology.

The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC

M. Tonn, B. Peters, E. M. van de Garde, 2021, Scientific Reports.